Document:

Exhibit 10.2

 

***Text Omitted and Filed Separately

With Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Section 200.80(b)(4)

and 240.24b-2

 

	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	1.CONTRACT
    ID CODE	 PAGEOFPAGES	 
	1	      23	 
	2.  AMENDMENT/MODIFICATION
    NO.	 3.  EFFECTIVE
    DATE	  4.  REQUISITION/PURCHASE
    REQ. NO.	 5.  PROJECT
    NO. (if applicable)	 
	0019	See
    Block 16C	OS139427	 	 
	6.  ISSUED
    BY	CODE	ASPR-BARDA	7.
                                         ADMINISTERED BY (If other than Item 6)

         
	CODE	ASPR-BARDA02	 
	ASPR-BARDA

        200 Independence Ave.,
        S.W.

        Room 640-G

        Washington DC 20201

         
	ASPR-BARDA

        330 Independence
        Ave, SW, Rm G640

        Washington DC
        20201

         
	 
	8.  NAME
    AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)	(x)	 9A.  AMENDMENT
    OF SOLICITATION NO.	 
	 

        CHIMERIX, INC. 1377270

        CHIMERIX, INC.2505
        MERIDIAN P

        2505 MERIDIAN PKWY STE
        340

        DURHAM NC 277135246
	 	 	 
	 9B.  DATED
    (SEE ITEM 11)	 
	 	 	 
	x	10A.
                                         MODIFICATION OF CONTRACT/ORDER NO.

        HHSO100201100013C
	 
	 	 	 
	10B.
                                         DATED (SEE ITEM 13)

        02/16/2011
	 
	CODE

        1377270
	FACILITY
    CODE	 	 
	11.  THIS
    ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS	 
	oThe
above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers           o
is extended.    o
is not extended Offers must acknowledge receipt of this
amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing
Items 8 and 15, and returning ___________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy
of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.
FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED
MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change
may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and
is received prior to the opening hour and date specified.
	 
	12.
                                         ACCOUNTING AND APPROPRIATION DATA (if required)                                       Net
                                         Increase:                                          $16,951,226.00

        ..2014.1992003.25106
	 
	13.  THIS
    ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.	 
	CHECK
    ONE	A. THIS
    CHANGE ORDER IS ISSUED PURSUANT TO:  (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE
    MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.	 
	 	 
	 	B. THE
    ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation
    date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).	 
	 	C. THIS
    SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:	 
	x	D. OTHER
                                         (Specify type of modification and authority)

        Bilateral:
      Mutual Agreement of the Parties and FAR Clause 52.217-9.
	 
	E.  IMPORTANT:             Contractor                        o  is
    not.            x  is
    required to sign this document and return         0        copies to the
    issuing     office.	 
	14.  DESCRIPTION
    OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)	 
	Tax
                                         ID Number:            33-0903395

        DUNS Number:     121785997

        A.            The purpose of this
        modification is for the Government to both bilaterally re-establish and exercise Option 2/CLIN 0003 of the contract in
        accordance with the terms and conditions of both Option 2/CLIN 0003 and the contract. The Government and the Contractor
        hereby bilaterally modify this contract for the purposes of both re-establishing and exercising

        the total amount of Option 2/CLIN 0003 in the amount of:

         

        Total Estimated Cost:
        $[...***...]

        Total Fixed Fee: $[...***...]

        Total Estimated Cost Plus
        Fixed Fee: $16,951,226.00

        Continued ...
	 
	Except
    as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
    unchanged and in full force and effect.	 
	15A.  NAME
    AND TITLE OF SIGNER (Type or print)	 16A.  NAME
    AND TITLE OF CONTRACTING OFFICER (Type or print)	 
	Michael
    Rogers, Chief Development Officer	ETHAN
    J. MUELLER	 
	15B.  CONTRACTOR/OFFEROR	 15C.  DATE
    SIGNED	16B.
                                         UNITED STATES OF AMERICA

                                                                                                                                   
	 16C.  DATE
    SIGNED	 
	/s/
Michael Rogers______________________	 	___________________________________________	 	 
	(Signature
                                         of person authorized to sign)
	8/27/14	(Signature
                                         of Contracting Officer)
	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	NSN 7540-01-152-8070	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	Prescribed by GSA
	 	FAR (48 CFR) 53.243

 

***Confidential
Treatment Requested 

 

    	 

    	 

    

 

	CONTINUATION
    SHEET	REFERENCE
        NO. OF DOCUMENT BEING CONTINUED

        HHSO100201100013C/0019
	PAGEOF
	2	      23
	NAME
        OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	ITEM
        NO.

        (A)
	SUPPLIES/SERVICES

        (B)
	QUANTITY

        (C)
	UNIT

        (D)
	UNIT
        PRICE

        (E)
	AMOUNT

        (F)

	 	 

                                                                                The
                                         total period of performance of Option 2/CLIN 0003 under the contract is from 1 September
                                         2014 through 30 November 2015.

                                                                                 

                                                                                1. 
                                         This modification hereby results in an increase in the total amount of the contract from
                                         $36,262,373.00 by $16,951,226.00 to $53,213,599.00 as well as the following:

                                                                                 

                                                                                Total
                                         Estimated Cost of the Contract: From $[...***...] By $[...***...]
                                         To $[...***...].

                                                                                 

                                                                                Total
                                         Fixed Fee of the Contract: From $[...***...] By $[...***...] To $[...***...].

                                                                                 

                                                                                Total
                                         Estimated Cost Plus Fixed Fee of the Contract: From $36,262,373.00 By $16,951,226.00
                                         To $53,213,599.00.

                                                                                 

                                                                                2. 
                                         Block 15G of the SF 26, the amount of $36,262,373.00 shall be changed to $53,213,599.00. 
                                         In Block 14 of the SF 26, the following CAN Number is added:

                                                                                 

                                                                                Appropriation
                                         Year: 2014, Object Class: 25106, CAN# 1992003 $16,951,226.00

                                                                                 

                                                                                3. 
                                         As a result, Attachment 1, Statement of Work dated 23 May 2013, under PART III, LIST
                                         OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS, SECTION J - LIST OF ATTACHMENTS is hereby
                                         deleted and replaced with the attached Statement of Work dated 31 July 2014.  The
                                         efforts within Option 2/CLIN 0003 that involve [...***...] and [...***...]
                                         cannot be performed until the receipt and approval of all required Protocols by BARDA
                                         inclusive of all IRB, OHRP approvals and any required Ethics Approvals for any clinical
                                         trials/studies and any required approved OLAW Assurances and IIA approvals from OLAW
                                         for any non clinical animal studies.

                                                                                 

                                                                                4. 
                                         The incorporation of the attached Statement of Work (SOW) changes in the paragraph above
                                         also result in the incorporation of the attached changes into the contract into WBS Milestones/Deliverables
                                         and Technical Deliverables and Contract Milestones and Go/No Go Decision Gates dated
                                         31 July 2014 under Article F.2. Deliverables.

                                                                                 

                                                                                5. 
                                         Total expenses for all domestic and foreign travel (transportation, lodging, subsistence,
                                         and incidental expenses) incurred in direct performance of this contract shall not exceed
                                         $[...***...] during the base segment/CLIN 0001, $[...***...] during
                                         Option Period 1/CLIN 0002 and $ [...***...] during Option Period 2/CLIN 0003
                                         without the prior written approval of the Contracting Officer.

                                                                                 

                                                                                6. 
                                         The first and second sentences in Article G.7. INDIRECT COST RATES of the contract are
                                         replaced with the following:

                                                                                 

                                                                                The
                                         following rates will be utilized for billing purposes during both the base period/CLIN
                                         0001, Option 1/CLIN 0002 and Option 2/CLIN 0003 ONLY.

                                                                                 

                                                                                Continued
                                         ...  

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 
	 	 	 	 
	 	 	 	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336 (4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

	CONTINUATION
    SHEET	REFERENCE
                                         NO. OF DOCUMENT BEING CONTINUED

        HHSO100201100013C/0019
	PAGEOF
	3	23
	NAME
                                         OF OFFEROR OR CONTACTOR

        CHIMERIX, INC. 1377270

	ITEM
                                         NO.

        (A)
	SUPPLIES/SERVICES

        (B)
	QUANTITY

        (C)
	UNIT

        (D)
	UNIT
                                         PRICE

        (E)
	AMOUNT

        (F)

	 	 

                                                                                                                    FY
                                         11 (Retroactive Adjustment base period/CLIN 0001 ONLY) - Fringe Benefits at [...***...]%
                                         and Indirect at [...***...]%.

                                                                                                                     

                                                                                                                    FY
                                         12 and FY 13 (Retroactive Adjustment and Billing, base period/CLIN 0001 ONLY and Billing,
                                         Option 1/CLIN 0002 and Option 2/CLIN 0003 ONLY) - Fringe Benefits at [...***...]%
                                         and Indirect at [...***...]%.

                                                                                                                     

                                                                                                                    7. 
                                         The total amount and scope of all other CLINs that are currently being performed under
                                         the contract remain unchanged. This modification does not exercise any unexercised Option
                                         CLINs under the contract and does not authorize any performance of efforts under any
                                         unexercised Option CLINs under the contract.  In addition, the total amount, scope
                                         and period of performance of all unexercised Option CLINs under the contract remain unchanged.
                                         This modification also confirms that all activities under the base period of performance
                                         CLIN 0001 were completed as of 31 May 2013.  The period of performance for Option
                                         1/CLIN 0002 of Contract Number HHSO100201100013C ONLY is hereby changed from 1 June 2013
                                         through 31 August 2014 to 1 June 2013 through 31 October 2014, at no additional cost
                                         to the Government.  The total amount and scope of Option 1/CLIN 0002 of Contract
                                         Number HHSO100201100013C remains unchanged.

                                                                                                                     

                                                                                                                    8. 
                                         The following clause is hereby added to Article I.1, Section I Contract Clauses of the
                                         contract:

                                                                                                                     

                                                                                                                    HHSAR
                                         352.231-70 Salary Rate Limitation (Aug 2012)

                                                                                                                     

                                                                                                                    B. 
                                         This is a bilateral modification.  All other terms and conditions contract number
                                         HHSO100201100013C remain unchanged.

                                                                                                                     

                                                                                                                    Delivery:
                                         11/30/2015

                                                                                                                    Delivery
                                         Location Code:   HHS

                                                                                                                    HHS

                                                                                                                    200
                                         Independence Avenue, SW

                                                                                                                    Washington
                                         DC 20201 US

                                                                                                                     

                                                                                                                    Appr.
                                         Yr.: 2014 CAN: 1992003 Object Class: 25106

                                                                                                                    FOB:
                                         Destination

                                                                                                                    Period
                                         of Performance: 02/16/2011 to 11/30/2015

                                                                                                                     

                                                                                                                    Change
                                         Item 3 to read as follows(amount shown is the obligated amount):

                                                                                                                     

                                                                                                                    [...***...]

                                                                                                                     

                                                                                                                    Reports
                                         and Other Data Deliverables.

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 
	 	 	 	 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                16,951,226.00

	 	 	 	 	 	 	 	 	 

	NSN 7540-01-152-8067	OPTIONAL FORM 336 (4-86)
	 	Sponsored by GSA
	 	FAR (48 CFR) 53.110

 

***Confidential
Treatment Requested

 

    	 

    	 

    

 

BARDA
Broad Agency Announcement (BAA)

(CBRN-BAA-10-100-SOL-00012)

Advanced Research and Development of Chemical,
Biological, Radiological, and

Nuclear Medical Countermeasures

DEVELOPMENT OF CMX-001 FOR THE TREATMENT
OF SMALLPOX

Topical Area of Interest No. 3, Antimicrobial
Drugs

 

Contractual Statement of Work

 

		1.	PREAMBLE

 

Independently and not as an agency of the
Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material, equipment, and
facilities, not otherwise provided by the Government, as needed to perform the Statement of Work submitted in response to the BARDA
Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00012.

 

In accordance with FAR 52.243-2, Changes-Cost
Reimbursement (Alt. V), the Government reserves the right to modify the milestones, progress, schedule, budget, or to add or delete
deliverables, process, or schedules if the need arises. Because of the nature of this research and development (R&D) contract
and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate whether work should
be redirected, removed, or whether schedule or budget adjustments should be made.

 

		1.0	Overall Objectives and Scope

 

The overall objective of this contract
is to advance the development of CMX-001 as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections and
dsDNA viruses. The scope of work for this contract includes preclinical, clinical and manufacturing development activities that
fall into the following areas: non-clinical efficacy studies; clinical activities; manufacturing activities; and all associated
regulatory, quality assurance, management, and administrative activities. The Research and Development (R&D) effort for the
antiviral will progress in specific stages that cover the base performance segment and four (4) option segments as specified in
this contract. The Contractor must complete specific tasks required in each of the five discrete work segments. The scope of work
has been broken into the following five phases which are discrete work segments:

		I.	[...***...]

		II.	[...***...]

		III.	[...***...]

		IV.	[...***...]

		V.	[...***...]

 

***Confidential Treatment Requested

 

    	1

    	 

    

 

		2.	PHASE I: [...***...]

Research and development of
CMX-001 for the treatment of smallpox and dsDNA viruses to include the following activities: [...***...]. The contractor
shall carry out the following tasks and subtasks and in accordance with an agreed upon Integrated Master Schedule and Integrated
Master Plan (defined in 2.1.8 and 2.1.9 below) which shall further detail the conduct of the specific tasks and subtasks.

 

		2.1	Program Management

 

The Contractor shall provide for the following
as outlined below and in the contract deliverables list (Article F.2):

 

		2.1.1	The overall management, integration and coordination
of all contract activities, including a technical and administrative infrastructure to ensure the efficient planning, initiation,
implementation, and direction of all contract activities;

 

		2.1.2	A Principal Investigator (PI) responsible for project
management, communication, tracking, monitoring and reporting on status and progress, and modification to the project requirements
and timelines, including projects undertaken by subcontractors; The contract deliverables list (reference), identifies all contract
deliverables and reporting requirements for this contract.

 

		2.1.3	Project Manager(s) with responsibility for monitoring
and tracking day-to-day progress and timelines, coordinating communication and project activities; costs incurred; and program
management; The contract deliverables list (reference), identifies all contract deliverables and reporting requirements for this
contract.

 

		2.1.4	A BARDA Liaison with responsibility for effective communication
with the Project Officer and Contracting Officer.

 

		2.1.5	Administrative and legal staff to provide development
of compliant subcontracts, consulting, and other legal agreements, and ensure timely acquisition of all proprietary rights, including
IP rights, and reporting all inventions made in the performance of the project.

 

		2.1.6	Administrative staff with responsibility for financial
management and reporting on all activities conducted by the Contractor and any subcontractors.

 

***Confidential Treatment Requested

 

    	2

    	 

    

 

		2.1.7	Contract Review Meetings.

		2.1.7.1	The Contractor shall participate in regular meetings
to coordinate and oversee the contract effort as directed by the Contracting and Project Officers. Such meetings may include,
but are not limited to, meeting of the Contractors and subcontractors to discuss clinical manufacturing progress, product development,
product assay development, scale up manufacturing development, clinical sample assays development, preclinical/clinical study
designs and regulatory issues; meetings with individual contractors and other HHS officials to discuss the technical, regulatory,
and ethical aspects of the program; and meeting with technical consultants to discuss technical data provided by the Contractor.

		2.1.7.2	The Contractor shall participate in teleconferences every
two weeks between the Contractor and subcontractors and BARDA to review technical progress. Teleconferences or additional face-to-face
meetings shall be more frequent at the request of BARDA.

		2.1.8	Integrated Master Schedule

		2.1.8.1	Within 30 calendar days of the effective date of the
contract, the Contractor shall submit a first draft of an updated Integrated Master Schedule in a format agreed upon by BARDA
to the Project Officer and the Contracting Officer for review and comment. The Integrated Master Schedule shall be incorporated
into the contract, and will be used to monitor performance of the contract. Contractor shall include the key milestones and Go/No
Go decision gates. The IMS for the period of performance will be mutually agreed upon at the PMBR

		2.1.9	Integrated Master Plan

		2.1.9.1	Work Breakdown Structure: The Contractor shall utilize
a WBS template agreed upon by BARDA for reporting on the contact. The Contractor shall expand and delineate the Contract Work
Breakdown Structure (CWBS) to a level agreed upon by BARDA as part of their Integrated Master Plan for contract reporting. The
CWBS shall be discernable and consistent. BARDA may require Contractor to furnish WBS data at the work package level or at a lower
level if there is significant complexity and risk associated with the task.

		2.1.9.2	GO/NO-GO Decision Gates: The Integrated Master Plan outlines
key milestones with “Go/No Go” decision criteria (entrance and exit criteria for each phase of the project). The project
plan should include, but not be limited to, milestones in manufacturing, non-clinical and clinical studies, and regulatory submissions.

		2.1.9.3	Earned Value Management System Plan: Subject to the requirements
under HHSAR Clause 352.234-4, the Contractor shall use principles of Earned Value Management System (EVMS) in the management of
this contract. The Seven Principles are:

		I.	Plan all work scope for the program to completion.

 

    	3

    	 

    

 

		II.	Break down the program work scope into finite pieces
that can be assigned to a responsible person or organization for control of technical, schedule, and cost objectives.

		III.	Integrate program work scope, schedule, and cost objectives
into a performance measurement baseline plan against which accomplishments may be measured. Control Changes to the baseline.

		IV.	Use actual cost incurred and recorded in accomplishing
the work performed.

		V.	Objectively assess accomplishments at the work performance level.

		VI.	Analyze significant variances from the plan, forecast
impacts, and prepare an estimate at completion based on performance to date and work to be performed.

		VII.	Use earned value information in the company’s management
processes.

 

Elements of EVMS
shall be applied to all Cost Plus Fixed Fee CLINs as part of the Integrated Master Project Plan, the Contractor shall submit a
written summary of the management procedures that it will establish, maintain and use to comply with EVMS requirements.

 

		2.1.10	Decision Gate Reporting: On completion of a stage of
the product development, as defined in the agreed upon Integrated Master Schedule and Integrated Master Plan, the Contractor shall
prepare and submit to the Project Officer and the Contracting Officer a Decision Gate Report that contains (i) sufficient detail,
documentation and analysis to support successful completion of the stage according to the predetermined qualitative and quantitative
criteria that were established for Go/No Go decision making; and (ii) a description of the next stage of product development to
be initiated and a request for approval to proceed to the next stage of product development.

 

		2.1.11	Risk Management Plan: The Contractor shall develop a
risk management plan within 90 days of contract award highlighting potential problems and/or issues that may arise during the
life of the contract, their impact on cost, schedule and performance, and appropriate remediation plans. This plan should reference
relevant WBS elements where appropriate. Updates to this plan shall be included every three months (quarterly) in the monthly
Project Status Report.

 

    	4

    	 

    

 

		2.1.12	Performance Measurement Baseline Review (PMBR): The Contractor
shall submit a plan for a PMBR to occur within 90 days of contract award. At the PMBR, the Contractor and BARDA shall mutually
agree upon the budget, schedule and technical plan baselines (Performance Measurement Baseline). These baselines shall be the
basis for monitoring and reporting progress throughout the life of the contract. The PMBR is conducted to achieve confidence that
the baselines accurately capture the entire technical scope of work, are consistent with contract schedule requirements, are reasonably
and logically planned, and have adequate resources assigned. The goals of the PMBR are as FOLLOWS:

 

		I.	Jointly assess areas such as the Contractor’s planning
for complete coverage of the SOW, logical scheduling of the work activities, adequate resources, and identification of inherent
risks

		II.	Confirm the integrity of the Performance Measurement
Baseline (PMB)

		III.	Foster the use of EVM as a means of communication

		IV.	Provide confidence in the validity of Contractor reporting

		V.	Identify risks associated with the PMB

		VI.	Present any revised PMBs for mutual agreement

		VII.	Present an Integrated Master Schedule: The Contractor
shall deliver an initial program level Integrated Master Schedule (IMS) that rolls up all time-phased WBS elements down to the
activity level. This IMS shall include the dependencies that exist between tasks. This IMS will be agreed to and finalized at
the PMBR. DI-MGMT-81650 may be referenced as guidance in creation of the IMS (see http://www.acq.osd.mil/pm/).

		VIII.	Present the Risk Management Plan

 

		2.1.13	Deviation Request: During the course of contract performance,
in response to a need to change IMS activities as baselined at the PMBR, the Contractor shall submit a Deviation Report. This
report shall request a change in the agreed-upon IMS and timelines. This report shall include: (i) discussion of the justification/rationale
for the proposed change; (ii) options for addressing the needed changes from the agreed upon timelines, including a cost-benefit
analysis of each option; and (iii) recommendations for the preferred option that includes a full analysis and discussion of the
effect of the change on the entire product development program, timelines, and budget.

 

		2.1.14	Monthly and Annual Reports: The Contractor shall deliver
Project Status Reports on a monthly basis. The reports shall address the items below cross referenced to the WBS, SOW, IMS, and
EVM:

		I.	Executive summary highlighting the progress, issues,
and relevant activities in manufacturing, non-clinical, clinical, and regulatory;

		II.	Progress in meeting contract milestones, detailing the
planned progress and actual progress during the reporting period, explaining any differences between the two and corrective steps;

 

    	5

    	 

    

 

		III.	Updated IMS;

		IV.	Updated EVM;

		V.	Updated Risk Management Plan (Every 3 months);

		VI.	Three month rolling forecast of planned activities;

		VII.	Progress of regulatory submissions;

		VIII.	Estimated and actual expenses;

 

		2.1.15	Data Management: The Contractor shall develop and implement
data management and quality control systems/procedures, including transmission, storage, confidentiality, and retrieval of all
contract data;

		2.1.15.1	Provide for the statistical design and analysis of data
resulting from the research;

		2.1.15.2	Provide raw data or specific analyses of data generated
with contract funding to the Project Officer, upon request.

 

		2.2	Non-Clinical Toxicology

		2.2.1	N/A (no scope)

 

		2.3	Non-Clinical

		2.3.1	Develop and validate [...***...] to lower [...***...].

		2.3.2	[...***...]: Conduct [...***...]
studies including [...***...] studies, [...***...], and [...***...] studies in [...***...].

		2.3.3	[...***...]

		2.3.3.1	Conduct [...***...] study in [...***...].

		2.3.3.2	Conduct [...***...] studies including [...***...]
studies, [...***...] studies including [...***...] for CMX-001 and [...***...] in [...***...].

		2.3.4	Use of [...***...] as a CMX-001 Surrogate in
[...***...] Studies.

		2.3.4.1	Dose [...***...] with [...***...]
to identify the concentration of the [...***...] in [...***...] associated with [...***...] of [...***...].

		2.3.5	Scaling of [...***...] to [...***...]
by conducting studies with [...***...] to determine [...***...] in [...***...].

		2.3.6	[...***...] determination of CMX001, [...***...]
and [...***...] in the [...***...].

		2.3.7	Conduct [...***...] experiments to demonstrate
[...***...] following effective [...***...] prior to [...***...].

		2.3.8	Conduct studies to optimize [...***...] in
[...***...].

		2.3.9	Conduct CMX001 [...***...] study in [...***...]
at a dose of CMX001 equivalent or less than [...***...] with treatment beginning at the [...***...]

 

***Confidential Treatment Requested

 

    	6

    	 

    

 

		2.4	Clinical

		2.4.1	Measurement of [...***...] levels in [...***...]
and correlate the [...***...] levels to studies conducted in [...***...].

		2.4.2	Conduct expanded access protocol ([...***...]).

		2.4.3	Analyze data and provide a Final Report for [...***...]
evaluation of CMX001 in patients ([...***...])

 

		2.5	Regulatory

		2.5.1	Engaging the FDA on a path to support the treatment
of smallpox indication with CMX-001

		2.5.2	Preparing materials for and requesting, scheduling
and participating in all meetings with the FDA, including meetings to review EUA and/or all other data packages;

		2.5.3	Providing BARDA with (i) the initial draft minutes
and final draft minutes of any formal meeting with the FDA; (ii) final minutes of any informal meeting with the FDA;

		2.5.4	Obtain FDA concurrence on the feasibility of the proposed
[...***...] with CMX001/[...***...]/[...***...] in the [...***...] ([...***...]),
including FDA feedback on [...***...] and review of data for the first [...***...] enrolled in the [...***...]
sub-study

		2.5.5	Develop and submit a revised [...***...]
for CMX001 for Treatment of Smallpox, including [...***...] for FDA review and comment, and revise the [...***...]
as requested by FDA

 

		2.6	CMC

		2.6.1	Validation of the [...***...] process: Validation
of the process to demonstrate the [...***...] of a [...***...] of acceptable quality will be performed.

		2.6.2	Validation of the [...***...] process to
produce [...***...]: Validation of the process to demonstrate the [...***...] of a [...***...] of
acceptable quality will be performed.

 

		3.	PHASE II: [...***...]

 

Research and
development of CMX001 for the treatment of smallpox to include the following activities: [...***...]. The contractor
shall carry out the following tasks and subtasks and in accordance with the agreed upon Integrated Master Schedule and Integrated
Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

***Confidential Treatment Requested

 

    	7

    	 

    

 

		3.1	Program Management (consistent with section 2.1)

		3.1.1	Program management scope in BASE year is consistent
with program management scope in each option year.

 

		3.2	Non-Clinical toxicology

		3.2.1	N/A (no scope)

 

		3.3	Non-Clinical

		3.3.1	Quantify [...***...] concentrations in [...***...]
from [...***...].

		3.3.2	Determine [...***...] for CMX001 in [...***...]
in [...***...].

		3.3.3	Scaling of [...***...] to [...***...]
- Review with BARDA and FDA the [...***...] generated to support scaling between [...***...] and [...***...]
using [...***...] as well as comparisons of [...***...] in the [...***...].

		3.3.4	Determine [...***...] for CMX001 in [...***...]
in [...***...].

		3.3.5	Conduct [...***...].

		3.3.6	Conduct [...***...] and [...***...]

		3.3.7	Chimerix will provide [...***...] for the
[...***...] and [...***...] conducted under [...***...]

 

		3.4	Clinical

		3.4.1	N/A (No scope)

 

***Confidential Treatment Requested

 

    	8

    	 

    

 

		3.5	Regulatory

		3.5.1	Engaging the FDA on a path to support the treatment
of smallpox indication with CMX001

		3.5.2	Generating all necessary documentation for [...***...].
[[...***...]]

		3.5.3	Preparing materials for and requesting, scheduling
and participating in all meetings with the FDA, including meetings to review EUA (if needed) and/or all other data packages;

		3.5.4	Providing BARDA with (i) the initial draft minutes
and final draft minutes of any formal meeting with the FDA relating to the smallpox program; (ii) final draft minutes of any informal
meeting with the FDA relating to the smallpox program.

 

		3.6	CMC

		3.6.1	N/A (No scope)

 

		4.	PHASE III:
[...***...]

 

Research and development
of CMX001 for the treatment of smallpox and dsDNA viruses to include the following activities: [...***...] Study, [...***...]
Study, [...***...]. The contractor shall carry out the following tasks and subtasks and in accordance with agreed upon
Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the
specific tasks and subtasks.

 

		4.1	Program Management (Consistent with section
2.1)

		4.1.1	Program management scope in BASE year is consistent
with program management scope in each option year.

 

		4.2	Non- Clinical toxicology

		4.2.1	N/A (no scope)

 

***Confidential Treatment Requested

 

    	9

    	 

    

 

		4.3	Non-Clinical

		4.3.1	[...***...] studies: A [...***...]
study will be conducted with the [...***...] of CMX001 selected based on the results of the [...***...] and
[...***...] studies. [...***...] will be [...***...] to receive [...***...] beginning
at the [...***...] or the FDA agreed upon trigger for treatment. The first [...***...] study will be a [...***...]
study of CMX001 in the [...***...] model. A study will be conducted with an [...***...] of CMX001 to determine
the [...***...] after observation of the FDA agreed upon trigger for treatment. These studies will include [...***...]
and [...***...]. The primary endpoint will be [...***...].

		4.3.2	[...***...] study of CMX001 in the [...***...]:
The [...***...] study will compare [...***...] with [...***...] agreed upon with FDA. The studies
will include [...***...] and [...***...] agreed upon with the FDA. The primary endpoint will be [...***...].

		4.3.3	Conduct additional studies in [...***...]
to determine [...***...] and [...***...] for CMX001 at [...***...].

		4.3.4	Conduct [...***...] of [...***...].

 

		4.4	Clinical

		4.4.1	Clinical [...***...] study to evaluate [...***...]
used in previous clinical studies and [...***...] developed for NDA. This study will [...***...] to [...***...]
to determine if [...***...] are comparable.

 

		4.5	Regulatory

		4.5.1	Generating all necessary data and preparing documentation
for an [...***...] meeting submissions to regulatory agencies;

		4.5.2	Preparing materials for and requesting, scheduling
and participating in all meetings with the FDA, including the [...***...] Meeting, meetings to review [...***...],
EUA (if needed) and/or all other data packages;

		4.5.3	Providing BARDA with (i) the initial draft minutes
and final draft minutes of any formal meeting with the FDA relating to this Contract; (ii) final draft minutes of any informal
meeting with the FDA;

		4.5.4	Preparing an [...***...] submission [...***...].

 

***Confidential Treatment Requested

 

    	10

    	 

    

 

		4.6	CMC

		4.6.1	[...***...] in order to generate [...***...]
for registration and clinical trial supplies.

 

		5.	PHASE IV: [...***...]

 

Research and
development of CMX-001 for the treatment of smallpox to include the following activities: [...***...], [...***...]
studies and phase I [...***...] study. The contractor shall carry out the following tasks and subtasks and in accordance
with agreed upon Integrated Master Schedule and Integrated Master Plan (defined in 2.1.8 and 2.1.9) which shall further detail
the conduct of the specific tasks and subtasks.

 

		5.1	Program Management (Consistent with section
2.1)

		5.1.1	Program management scope in BASE year is consistent
with program management scope in each option year.

 

		5.2	Non-Clinical toxicology

		5.2.1	N/A (no scope)

 

		5.3	Non-Clinical

		5.3.1	[...***...] studies. [...***...]
will be randomized to receive [...***...] beginning at the [...***...]. These studies will include [...***...]
and [...***...] as well as [...***...] including [...***...]. The primary endpoint will be [...***...]

		5.3.2	[...***...] Studies. This study will determine
the [...***...] at the [...***...]. [...***...] and [...***...] at the [...***...].
The primary endpoint will be [...***...]. If FDA requires a [...***...] in the [...***...] studies,
the [...***...] study may not be needed.

		5.3.3	Conduct [...***...] Studies. This study
will determine the [...***...] at the [...***...]. [...***...] and [...***...] at the
[...***...].

 

***Confidential Treatment Requested

 

    	11

    	 

    

 

		5.4	Clinical

		5.4.1	Phase 3 development including [...***...]
study, [...***...] study, phase II [...***...] study. A [...***...] study will be conducted to compare
the [...***...] of CMX001 in [...***...] to [...***...]. A [...***...] study will be conducted
to compare the [...***...] of CMX001 when [...***...]. A [...***...] study will be conducted (if
required) to [...***...] to support an NDA.

		5.4.2	Measurement of [...***...] in [...***...]
and correlate the [...***...] to studies conducted in [...***...] (if required).

		5.4.3	Compile [...***...] for NDA submission.
A [...***...] collected from all CMX001 clinical studies, irrespective of indication, will be populated and analyzed
in order to support an NDA for smallpox.

 

		5.5	Regulatory

		5.5.1	Generating all necessary data and preparing documentation
for NDA submissions to regulatory agencies;

		5.5.2	Preparing materials for and requesting, scheduling
and participating in all meetings with the FDA, including meetings to review IND, EUA and/or all other data packages;

		5.5.3	Providing BARDA with (i) the initial draft minutes
and final draft minutes of any formal meeting with the FDA; (ii) final draft minutes of any informal meeting with the FDA

 

		5.6	CMC

		5.6.1	[...***...]. [...***...] of the
process to demonstrate the [...***...] of a [...***...] will be performed.

 

		6.	PHASE V: [...***...]

7.          

Research and development
of CMX-001 for the treatment of smallpox to include the following activities: [...***...]. The contractor shall carry
out the following tasks and subtasks and in accordance with an agreed upon Integrated Master Schedule and Integrated Master Plan
(defined in 2.1.8 and 2.1.9) which shall further detail the conduct of the specific tasks and subtasks.

 

		7.1	Program Management (Consistent with section
2.1)

		7.1.1	Program management scope in BASE year is consistent
with program management scope in each option year.

 

***Confidential Treatment Requested

 

    	12

    	 

    

 

		7.2	Non-Clinical toxicology

		7.2.1	N/A (no scope)

 

		7.3	Non-Clinical

		7.3.1	[...***...] Studies. This study replicates
[...***...] if a larger sample size is necessary to achieve a [...***...] result.

 

		7.4	Clinical

		7.4.1	Compile [...***...]. A database of [...***...]
data collected from all CMX001 clinical studies, irrespective of [...***...], will be populated and analyzed in order
to support an NDA for smallpox.

 

		7.5	Regulatory

		7.5.1	Generating all necessary data and preparing documentation
for NDA submissions to regulatory agencies;

		7.5.2	Submitting NDA documentation to the FDA in a timely
manner, consistent with timelines set out in the contract and by the FDA.

		7.5.3	Preparing materials for and requesting, scheduling
and participating in all meetings with the FDA, including meetings to review IND, EUA and/or all other data packages;

		7.5.4	Providing BARDA with (i) the initial draft minutes
and final draft minutes of any formal meeting with the FDA; (ii) final draft minutes of any informal meeting with the FDA;

 

		7.6	CMC

		7.6.1	[...***...]. [...***...] of the
process to demonstrate the [...***...] of a [...***...] will be performed.

 

		8.	Other Items

 

		8.1	Facilities, Equipment and Other Resources. (Contract:
Section J)

The Contractor
shall provide equipment; facilities and other resources required for implementation of the SOW dated January 11, 2011[insert
approval date] to comply with all Federal and HHS regulations in:

 

***Confidential Treatment Requested

 

    	13

    	 

    

 

		8.1.1	The [...***...] and use of [...***...];

		8.1.2	The acquisition, handling, storage and shipment of
[...***...], including [...***...] required for working with the [...***...];

		8.1.3	The [...***...] of [...***...]
under cGMP;

		8.1.3.1	The design and conduct of [...***...]; and

		8.1.3.2	The conduct of [...***...] studies to determine
[...***...] of [...***...]

 

		8.1.4	Design and conduct of [...***...] under
GCP.

 

***Confidential Treatment Requested

 

    	14

    	 

    

 

	REVISED MILESTONES ARTICLE F.2 DELIVERABLES
	 
	Current

Milestone #	 	Milestone Definition	 	Go Criteria	 	No-Go Criteria	 	Deliverable	 	WBS/SOW #	 	Segment
	1.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	2.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	3.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	4.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	5.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	6.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	7.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	8.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	9.	 	No longer in development plan.	 	 	 	 	 	 	 	N/A	 	N/A
	10.	 	No longer in development plan.	 	 	 	 	 	 	 	N/A	 	N/A
	11.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	12.	 	No longer in development plan.	 	 	 	 	 	 	 	N/A	 	N/A
	13.	 	No longer in development plan.	 	 	 	 	 	 	 	N/A	 	N/A
	14.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	15.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	16.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	17.	 	No longer in development plan.	 	 	 	 	 	 	 	N/A	 	N/A
	18.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	19.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	20.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	21.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	22.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	23.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	24.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	25.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	26.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	BCA MILESTONE	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	NEW OPTION 1 MILESTONE TO BE ADDED TO ARTICLE F.2 DELIVERABLES OF THE CONTRACT
	28.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 

***Confidential Treatment Requested

 

    	 

    	 

    

 

	29.	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 

***Confidential Treatment RequestedExhibit 10.4

 

FIFTH AMENDMENT TO
OFFICE LEASE

 

THIS FIFTH AMENDMENT
TO OFFICE LEASE (this “Fifth Amendment”) is made as of this 2nd day of July, 2014 (the “Effective
Date”), by and between AREP MERIDIAN I LLC, a Delaware limited liability company (“Landlord”), and CHIMERIX,
INC., a Delaware corporation (“Tenant”).

 

W I T N E S S E T H:

 

WHEREAS, pursuant
to that certain Office Lease dated September 1, 2007 (the “Original Lease”), ACP 2505 Meridian LLC (“Original
Landlord”) leased to Tenant, and Tenant leased from Original Landlord, approximately 6,849 rentable square feet of office
space (the “Original Premises”) known as Suite 340 on the third (3rd) floor of the building located at 2505
Meridian Parkway, Durham, North Carolina 27713 (the “Building”);

 

WHEREAS, pursuant
to that certain First Amendment to Office Lease dated December 19, 2008 (the “First Amendment”), Original Landlord
and Tenant amended the Original Lease to provide for the demise to Tenant of the Additional Premises (as more particularly described
in the First Amendment), upon the terms and conditions set forth in the First Amendment;

 

WHEREAS, pursuant
to that certain Second Amendment to Office Lease dated January 21, 2011 (the “Second Amendment”), Original Landlord
and Tenant amended the Original Lease, as amended, to provide for the extension of the Term until February 29, 2012;

 

WHEREAS, Landlord
has succeeded to the interest of Original Landlord under the Original Lease, as amended;

 

WHEREAS, pursuant
to that certain Third Amendment to Office Lease dated March 1, 2012 (the “Third Amendment”), Landlord and Tenant amended
the Original Lease, as amended, to provide for the extension of the Term until February 28, 2013;

 

WHEREAS, pursuant
to that certain Fourth Amendment to Office Lease dated February 13, 2013 (the “Fourth Amendment”), Landlord and Tenant
amended the Original Lease, as amended, to provide for the extension of the Term until February 28, 2018; and

 

WHEREAS, Landlord
and Tenant desire to amend the Original Lease, as amended, to provide for the demise to Tenant of the Second Additional Premises
(hereinafter defined), all upon the terms and conditions set forth in this Fifth Amendment.

 

NOW, THEREFORE,
in consideration of the foregoing and for other good and valuable consideration and of the mutual agreements hereinafter set forth,
it is hereby mutually agreed as follows:

 

1.Incorporation
of Recitals. The foregoing recitals are hereby incorporated in this Fifth Amendment and are made a part hereof by this reference.

 

2.Definitions.
All capitalized terms not defined in this Fifth Amendment shall have the meanings ascribed thereto in the Original Lease, as amended.
As used herein and in the Original Lease, as amended (i) the term “Lease” shall mean the Original Lease, as amended
by the First Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment and this Fifth Amendment and (ii) the term
“Premises” shall mean (a) for the period commencing on the Effective Date of this Fifth Amendment until the date immediately
preceding the Second Additional Premises Commencement Date (hereinafter defined), the Original Premises together with the Additional
Premises and (b) from and after the Second Additional Premises Commencement Date, the Original Premises together with the Additional
Premises and the Second Additional Premises.

 

    	 

    	 

    

 

3.Second Additional
Premises; Second Additional Premises Commencement Date. Subject to the terms and conditions set forth herein, Landlord hereby
leases to Tenant, and Tenant hereby leases from Landlord, for a term beginning on the Second Additional Premises Commencement Date
and ending on February 28, 2018 (i.e. the “Expiration Date” under the Original Lease, as amended), unless extended
or earlier terminated in accordance with the terms of the Lease, approximately 6,836 rentable square feet of office space currently
known as Suite 100 comprising a portion of the first (1st) floor of the Building (the “Second Additional Premises,”
as shown on the attached Exhibit A). From and after the Second Additional Premises Commencement Date, the aggregate number
of rentable square feet demised to Tenant under the Lease (consisting of the Original Premises, the Additional Premises and the
Second Additional Premises) is 17,892. As used herein, the term “Second Additional Premises Commencement Date” means
the date that is the earlier to occur of (i) the date on which Landlord substantially completes (hereinafter defined) the Tenant
Improvements described in the Work Agreement attached hereto as Exhibit B (the “Work Agreement”), or, if there
occurs any Tenant Delay (as such term is defined in the Work Agreement), the date on which Landlord would have substantially completed
the Tenant Improvements but for such Tenant Delay and (ii) the date on which Tenant, or anyone claiming by, through or under Tenant,
first commences use or occupancy of any portion of the Second Additional Premises for the conduct of its business. The Tenant Improvements
shall be deemed “substantially complete” on the date that (a) all items of the Tenant Improvements, excluding Long
Lead Items (as defined in the Work Agreement), have been completed, subject only to punch list items of work which do not substantially
interfere with Tenant’s use of the Second Additional Premises for general office use and (b) Landlord has obtained and delivered
to Tenant final inspection from City of Durham inspectors with respect to all open permits relating to the Tenant Improvements
which permit Tenant to occupy the Second Additional Premises. Landlord shall use commercially reasonable efforts to obtain a certificate
of occupancy for the Second Additional Premises within thirty (30) days after the date on which Landlord substantially completes
the Tenant Improvements. Reference is made to the form of Declaration of Second Additional Premises Commencement Date (the “Second
Additional Premises Declaration”) attached hereto as Exhibit C. After the Second Additional Premises Commencement
Date, Landlord shall complete the Second Additional Premises Declaration and deliver the completed Second Additional Premises Declaration
to Tenant. Within five (5) business days after Tenant receives the completed Second Additional Premises Declaration from Landlord,
Tenant shall execute and return the Second Additional Premises Declaration to Landlord to confirm the Second Additional Premises
Commencement Date. Failure to execute the Second Additional Premises Declaration shall not delay or otherwise affect the occurrence
of the Second Additional Premises Commencement Date.

 

4.Improvements
to the Second Additional Premises. Landlord shall construct in the Second Additional Premises, at Landlord’s sole cost
and expense (except as otherwise set forth herein and in the Work Agreement), the Tenant Improvements described in the Work Agreement
in accordance with the terms of the Work Agreement. In the event that Landlord and Tenant have not finally agreed upon the scope
and details of the Tenant Improvements as of the Effective Date of this Fifth Amendment, the submission of plans and specifications
detailing such work shall be subject to Landlord’s or Tenant’s written approval in accordance with the terms of the
Work Agreement. Landlord shall not be liable for any delay in the completion of the Tenant Improvements or any delay in the delivery
of the Second Additional Premises to Tenant. Notwithstanding the foregoing, if the Second Additional Premises Commencement Date
has not occurred on or before December 1, 2014 (the “Delay Abatement Date”), then, the Base Rent payable with respect
to the Second Additional Premises only shall be abated for a period commencing on the Second Additional Premises Commencement Date
and continuing for a number of consecutive days equal to the number of days after the Delay Abatement Date that the Second Additional
Premises Commencement Date failed to occur. The Delay Abatement Date shall be extended by one (1) day for each day that the Second
Additional Premises Commencement Date is delayed as the result of any Tenant Delay or event of force majeure.

 

    	2

    	 

    

 

5.Base Rent.
From and after the Effective Date of this Fifth Amendment until the date immediately preceding the Second Additional Premises Commencement
Date, Tenant shall continue to pay Landlord Base Rent for the Original Premises and Additional Premises pursuant to the terms and
conditions of the Original Lease, as amended. From and after the Second Additional Premises Commencement Date, and thereafter on
the first day of each and every calendar month during the Term, Tenant shall pay Landlord Base Rent for the entire Premises (i.e.
the Original Premises together with the Additional Premises and the Second Additional Premises) in the following amounts, in equal
monthly installments, in advance, and, accordingly, as of the Second Additional Premises Commencement Date, the Base Rent chart
set forth in Paragraph 5 of the Fourth Amendment (captioned, “Base Rent”) is hereby deleted in its entirety
and the following Base Rent chart is inserted in lieu thereof:

 

	Period	Base Rent Per Square Foot	Base Rent	Monthly Base 

Rent
	Second Additional Premises Commencement Date – 2/28/15	$20.50	$366,786.00*	$30,565.50
	3/1/15 – 2/29/16	$21.01	$375,910.92	$31,325.91
	3/1/16 – 2/28/17	$21.54	$385,393.68	$32,116.14
	3/1/17 – 2/28/18	$22.08	$395,055.36	$32,921.28
	[*on an annualized basis]

 

Tenant shall pay Landlord
Base Rent due pursuant to this Paragraph 5 in accordance with the terms and conditions of Section 3 of the Original Lease (captioned,
“Base Rent and Additional Rent”).

 

6.Tenant’s
Share of Increases in Taxes and Expenses. Tenant hereby expressly acknowledges and agrees that (i) from and after the Effective
Date of this Fifth Amendment until the date that is the later to occur of (a) the date immediately preceding the Second Additional
Premises Commencement Date and (b) December 31, 2014, Tenant shall continue to pay Landlord in accordance with the terms of the
Original Lease, as amended, Tenant’s Share of Taxes in excess of the Taxes incurred during the Fourth Amendment Base Tax
Year and Tenant’s Share of Expenses in excess of the Expenses incurred during the Fourth Amendment Base Expense Year and
(ii) notwithstanding anything to the contrary contained in the Original Lease, as amended, commencing on the later to occur of
(A) the Second Additional Premises Commencement Date and (B) January 1, 2015, and continuing thereafter during the balance of the
Term, Tenant shall pay Landlord, in accordance with the terms Section 3 of the Original Lease, as amended by the terms of this
Paragraph 6 (1) Tenant’s New Share (hereinafter defined) of Taxes in excess of the Taxes incurred during the Fifth Amendment
Base Tax Year (hereinafter defined) and (2) Tenant’s New Share of Expenses in excess of the Expenses incurred during the
Fifth Amendment Base Expense Year (hereinafter defined). As used herein (x) the term “Fifth Amendment Base Tax Year”
means calendar year 2014, (y) the term “Fifth Amendment Base Expense Year” means calendar year 2014 and (z) the term
“Tenant’s New Share” means 42.33%.

 

7.Brokers.
Landlord and Tenant recognize CBRE, Inc. (“Landlord Broker”), as Landlord’s agent, and Cushman & Wakefield
/ Thalhimer (“Tenant Broker”), as Tenant’s agent, with respect to this Fifth Amendment. Landlord agrees to be
responsible for the payment of any leasing commission or any other costs or fees owed to Tenant Broker and Landlord Broker in accordance
with the terms of a separate commission agreement entered into between Landlord and each of Landlord Broker and Tenant Broker.
Landlord and Tenant each represent and warrant to the other that no other broker has been employed in carrying on any negotiations
relating to this Fifth Amendment and shall each indemnify and hold harmless the other from any claim for brokerage or other commission
arising out of (a) any breach of the foregoing representation and warranty; or (b) the actions of Landlord or Tenant with respect
to the broker making any claim for a commission.

 

    	3

    	 

    

 

8.Option to
Extend Term.

 

A.Tenant shall
have and is hereby granted the option to extend the Term hereof for one (1) period of three (3) years (the “Fifth Extension
Period”) provided that: (i) Tenant delivers written notice (the “Extension Notice”) to Landlord, no earlier than
twelve (12), and no later than nine (9), months prior to the Expiration Date, time being of the essence, of Tenant’s irrevocable
election to exercise such extension option; (ii) no default by Tenant under the Lease exists at the time of Landlord’s receipt
of the Extension Notice or as of the first day of the Fifth Extension Period; and (iii) Tenant has not assigned its interest in
the Lease (other than to a Qualified Tenant Affiliate [hereinafter defined]) or sublet more than twenty percent (20%) of the Premises
(other than to a Qualified Tenant Affiliate).

 

B.All terms
and conditions of the Lease shall remain in full force and effect during the Fifth Extension Period, except that Base Rent (on
a per rentable square foot basis) payable during the Fifth Extension Period shall equal the Fair Market Rental Rate (hereinafter
defined) at the time of the commencement of the Fifth Extension Period. As used herein, the term “Fair Market Rental Rate”
shall mean the fair market rental rate that would be agreed upon between a landlord and a tenant entering into a lease for comparable
space as to location, configuration, size and use, in a comparable building as to quality, age, reputation and location in the
Raleigh / Durham, North Carolina area, which Fair Market Rental Rate shall take into consideration any then applicable market tenant
concessions for renewal tenants with credit similar to the credit of Tenant at the time of the determination of the Fair Market
Rental Rate.

 

C.Landlord
and Tenant shall negotiate in good faith to determine the Base Rent for the Fifth Extension Period for a period of thirty (30)
days after the date on which Landlord receives the Extension Notice from Tenant. In the event Landlord and Tenant are unable to
agree upon the Base Rent for the Fifth Extension Period within said thirty (30)-day period, the Fair Market Rental Rate shall be
determined by a board of three (3) licensed real estate brokers, one of whom shall be named by Landlord, one of whom shall be named
by Tenant, and the two so appointed shall select a third (the “Third Broker”). Each real estate broker so selected
shall be licensed in the State of North Carolina as a real estate broker specializing in the field of office leasing in the Raleigh
/ Durham, North Carolina area, having no fewer than ten (10) years experience in such field, and recognized as ethical and reputable
within the field. Landlord and Tenant agree to make their appointments promptly within ten (10) days after the expiration of the
thirty (30)-day period, or sooner if mutually agreed upon. The two (2) brokers selected by Landlord and Tenant shall select the
Third Broker within ten (10) days after they both have been appointed, and all three (3) brokers shall, within fifteen (15) days
after the Third Broker is selected, submit his or her determination of the Fair Market Rental Rate. The Third Broker shall determine
which determination of Fair Market Rental Rate made by Landlord’s broker or Tenant’s broker is closest to the determination
of Fair Market Rental Rate made by the Third Broker (the “Closest Determination”). The Fair Market Rental Rate hereunder
shall be the mean of the Closest Determination and the determination of Fair Market Rental Value made by the Third Broker. Landlord
and Tenant shall each pay the fee of the broker selected by it, and they shall equally share the payment of the fee of the Third
Broker.

 

D.Should the
Term be extended hereunder for the Fifth Extension Period, Tenant shall, if required by Landlord, execute an amendment (the “Extension
Amendment”) modifying the Lease within ten (10) business days after Landlord drafts and presents same to Tenant, which amendment
shall accurately set forth the Base Rent for each year of the Fifth Extension Period (as determined pursuant to the terms of this
Paragraph 8) and any other economic terms and provisions in effect during the Fifth Extension Period mutually agreeable to Landlord
and Tenant. Should Tenant fail to execute such amendment within such ten (10) business days period, time being of the essence,
Tenant’s right to extend the Term for the Fifth Extension Period shall, at Landlord’s sole option, terminate, and Landlord
shall be permitted to lease such space to any other person or entity upon whatever terms and conditions are acceptable to Landlord
in its sole discretion.

 

    	4

    	 

    

 

E.As of the
Effective Date of this Fifth Amendment, Paragraph 8 of the Fourth Amendment (captioned, “Option to Extend Term”) is
hereby deleted in its entirety and is of no further force and effect.

 

9.Right of First
Offer.

 

A.Commencing
on the Second Additional Premises Commencement Date, but subject to (i) any expansion rights, renewal rights, rights of first offer
or refusal or other rights possessed by any tenant in the Building with respect to the Right of First Offer Space (hereinafter
defined) or any portion thereof existing as of the Second Additional Premises Commencement Date, (ii) any renewal rights granted
by Landlord after the Effective Date of this Fifth Amendment to any tenant of all or any portion of the Right of First Offer Space
and (iii) the right of any tenant of the Right of First Offer Space (or any portion thereof) to negotiate an extension of the term
of its lease of such space or a new lease demising such space, Tenant shall be granted during the Term the following right with
respect to the Right of First Offer Space. As used herein, the term “Right of First Offer Space” shall mean (a) any
space on the first (1st) floor of the Building (other than the Premises) and/or (b) any space on the second (2nd)
floor of the Building and/or (c) that certain portion of the third (3rd) floor of the Building that Tenant is currently
subleasing from MDXHealth, Inc. Notwithstanding any provision of the Lease to the contrary, Tenant shall have no rights with respect
to the Right of First Offer Space or any other rights of first offer or refusal, or first right to negotiate, or any other expansion
rights whatsoever, except as expressly provided in this Paragraph 9.

 

B.In the event
that any Right of First Offer Space becomes or is reasonably anticipated by Landlord to become vacant and available to lease by
Tenant during the Term (following the expiration or earlier termination of an initial letting of any Right of First Offer Space
that is vacant as of the Second Additional Premises Commencement Date, including any renewal or extension periods for such letting),
then, subject to the terms of this Paragraph 9, Landlord shall notify Tenant in writing (the “ROFO Notice”) of such
availability, and Landlord shall set forth in the ROFO Notice: (a) a description of the available Right of First Offer Space (the
“ROFO Available Space”), (b) the base rent payable with respect to the ROFO Available Space, which base rent shall
be comparable to the base rental rates then being offered to tenants entering into a lease for comparable space as to location,
configuration, size and use, in a comparable building as to location, quality, reputation and age in the Raleigh / Durham, North
Carolina area for a comparable term and (c) the date on which Landlord anticipates that the ROFO Available Space would become available
for lease by Tenant (the “ROFO Availability Date”). Provided that (1) no default by Tenant then exists under the Lease;
(2) Tenant has not assigned the Lease (other than to a Qualified Tenant Affiliate) or sublet twenty percent (20%) or more of the
Premises (other than to a Qualified Tenant Affiliate); (3) not less than twenty-four (24) months remain in the Term as of the ROFO
Avail ability Date; and (4) Tenant notifies Landlord, in writing, within ten (10) days after Tenant receives the ROFO Notice, time
being of the essence, of Tenant’s irrevocable election to lease all (but not less than all) of the ROFO Available Space described
in the ROFO Notice on the terms and conditions set forth in the ROFO Notice (the “ROFO Tenant Election Notice”), Tenant
shall have the right to lease all, but not less than all, of the ROFO Available Space described in the ROFO Notice on the terms
and conditions set forth in the ROFO Notice.

 

C.In the event
that Tenant timely delivers a ROFO Tenant Election Notice to Landlord, Landlord shall prepare an amendment modifying the Lease
to incorporate the ROFO Available Space (the “ROFO Amendment”), which amendment shall set forth, among other things:
(i) the amount of Annual Base Rent for the ROFO Available Space; and (ii) the adjustments to Tenant’s obligation to pay Additional
Rent caused by the addition of the ROFO Available Space. The term of the demise of the ROFO Available Space shall be co-terminus
with the Term of the Lease and shall commence on the date on which Landlord delivers such ROFO Available Space to Tenant (the “ROFO
Space Commencement Date”), at which time all of Tenant’s obligations with respect to the ROFO Available Space shall
commence, including the obligation to pay Annual Base Rent.

 

    	5

    	 

    

 

D.In the event
that Landlord and Tenant enter into a ROFO Amendment, and Landlord is unable to deliver to Tenant possession of the ROFO Available
Space demised thereunder on the ROFO Availability Date for any reason whatsoever, including without limitation the failure of an
existing tenant to vacate such space, Landlord shall not be liable or responsible for any claims, damages or liabilities in connection
therewith or by reason thereof, provided that Landlord shall use reasonable efforts to obtain possession of such space and deliver
same to Tenant as soon as reasonably practicable thereafter.

 

E.In the event
Tenant fails to timely deliver a ROFO Tenant Election Notice to Landlord or, having done so, Tenant fails to execute the ROFO Amendment
(which accurately reflects the terms of the ROFO Notice) tendered by Landlord within ten (10) business days after Landlord tenders
such amendment to Tenant, this Paragraph 9 shall immediately terminate and Landlord may lease the ROFO Available Space (or any
portion thereof) described in the ROFO Notice to any person or entity of Landlord’s choice, on whatever terms and conditions
are selected by Landlord in its sole discretion.

 

F.Tenant’s
rights under this Paragraph 9 are personal to Chimerix, Inc. and can not be exercised by any assignee, subtenant or any other person
or entity (other than a Qualified Tenant Affiliate).

 

10.Exterior
Building Sign. After the Second Additional Premises Commencement Date, in the event that Tenant is then leasing at least 17,892
rentable square feet of space in the Building and Tenant is then in occupancy of at least 13,419 rentable square feet of space
in the Building, Tenant, at Tenant’s sole cost and expense, shall have the non-exclusive right to install one (1) exterior
building sign (the “Exterior Building Sign”) containing Tenant’s name and/or Tenant’s corporate logo. The
Exterior Building Sign shall be located on the parapet of the Building in a location approved by Landlord and Tenant, which approval
by Landlord and Tenant shall not be unreasonably withheld, conditioned or delayed. Tenant shall install the Exterior Building Sign
provided that (i) the Exterior Building Sign is permitted under, and conforms to, any covenants, conditions or restrictions affecting
the business park of which the Building is a part and any applicable laws, rules and regulations, including the requirements of
the City of Durham, Durham County and the State of North Carolina, and (ii) Tenant has obtained all permits, licenses and approvals
that may be required in order to install the Exterior Building Sign, including without limitation the approval of any owners association
with respect to the business park of which the Building is a part. The exact size, style, design, dimensions and other components
of the Exterior Building Sign shall be subject to Landlord’s approval. Landlord reserves the right to approve in its sole
discretion the manner in which the Exterior Building Sign is affixed to the Building. In order to obtain Landlord’s approval,
Tenant must submit to Landlord for Landlord’s approval samples of materials to be used for the Exterior Building Sign (showing,
among other things, the thickness thereof), samples of any colors to be used for the Exterior Building Sign, complete shop drawings
of the Exterior Building Sign and plans and specifications for the actual construction and attachment of the Exterior Building
Sign. The Exterior Building Sign shall be installed by a contractor reasonably approved by Landlord and maintained by a contractor
reasonably acceptable to Landlord. On or before the end of the Term, or in the event that Tenant assigns this Lease, or in the
event Tenant is no longer leasing at least 17,892 rentable square feet of space in the Building, or in the event Tenant is no longer
in occupancy of at least 13,419 rentable square feet of space in the Building, Tenant shall, at Tenant’s sole cost and expense,
have a contractor reasonably approved by Landlord remove the Exterior Building Sign and restore the portions of the Building affected
thereby to the condition which existed immediately prior to the installation of the Exterior Building Sign. If Tenant fails to
timely remove the Exterior Building Sign or fails to restore the Building in accordance with the terms of the immediately preceding
sentence, Landlord shall have the right, but not the obligation, to undertake such removal and/or restoration and Tenant shall
reimburse Landlord for all costs incurred by Landlord in connection therewith, immediately upon demand therefor. Tenant shall obtain
property insurance coverage for the Exterior Building Sign and such Exterior Building Sign shall be included in Tenant’s
comprehensive liability insurance required pursuant to the Lease. Tenant’s rights under this Paragraph 10 are personal to
Chimerix, Inc. and no assignee or sublessee of Chimerix, Inc. shall have any exterior signage rights hereunder. Tenant hereby agrees
to indemnify and hold Landlord and its agents, officers, directors and employees harmless from and against any cost, damage, claim,
liability or expense (including reasonable attorneys’ fees) incurred by or claimed against Landlord and its agents, officers,
directors and employees, directly or indirectly, as a result of or in any way arising from the installation, maintenance, repair,
operation, removal or existence of the Exterior Building Sign. Notwithstanding anything to the contrary contained in this Paragraph
10, if the Lease is assigned by Tenant to a Qualified Tenant Affiliate in accordance with the terms of the Lease, and provided
that Landlord permits in writing such Qualified Tenant Affiliate to install an exterior sign on the Building, then, subject to
the terms of this Paragraph 10, such Qualified Tenant Affiliate shall have the right to install one (1) sign on the exterior of
the Building in accordance with the terms of this Paragraph 10, provided, however, that the Exterior Building Sign installed by
Tenant has been previously removed from the Building in accordance with the terms of this Paragraph 10.

 

    	6

    	 

    

 

11.Additional
Modifications. As of the date of this Fifth Amendment, Paragraph 9 of the Fourth Amendment (captioned, “Expansion Option”)
and Paragraph 10 of the Fourth Amendment (captioned, “Tenant’s Termination Option”) are hereby deleted in their
entirety and are of no further force and effect.

 

12.Qualified
Tenant Affiliate. As used herein, the term “Qualified Tenant Affiliate” means a corporation or other business entity
which shall control, be controlled by or be under common control with Tenant or which results from a merger with Tenant or which
acquires all or substantially all of the business and assets of Tenant. For purposes of the immediately preceding sentence, “control”
shall be deemed to be ownership of more than fifty percent (50%) of the legal and equitable interest of the controlled corporation
or other business entity.

 

13.Memorandum
of Lease. Upon request of Tenant, Landlord shall execute a recordable memorandum of lease, in the form attached to this Fifth
Amendment as Exhibit D, which memorandum of lease shall be prepared and recorded in the public record at Tenant’s
sole cost and expense.

 

14.Counterpart
Copies. This Fifth Amendment may be executed in two (2) or more counterpart copies, all of which counterparts shall have the
same force and effect as if all parties hereto had executed a single copy of this Fifth Amendment.

 

15.Miscellaneous.
This Fifth Amendment (a) shall be binding upon and inure to the benefit of the parties hereto and their respective representatives,
transferees, successors and assigns and (b) shall be governed by and construed in accordance with the laws of the State of North
Carolina.

 

16.Ratification.
Except as expressly amended by this Fifth Amendment, all other terms, conditions and provisions of the Original Lease, as amended,
are hereby ratified and confirmed and shall continue in full force and effect.

 

    	7

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Fifth Amendment to Office Lease under seal as of the day and year first hereinabove written.

 

	 	LANDLORD:
	 	 	 
	 	AREP MERIDIAN I LLC,
	 	a Delaware limited liability company
	 	 
	 	 	 
	 	By:	/s/ Douglas Fleit
	 	 	Name:  Douglas Fleit
	 	 	Title:  President
	 	 	 
	 	 	 
	 	TENANT:
	 	 	 
	 	CHIMERIX, INC.,
	 	a Delaware corporation
	 	 
	 	 	 
	 	By: 	/s/ M. Berrey
	 	 	Name:  M. Berrey
	 	 	Title:  CEO

 

    	8

    	 

    

 

EXHIBIT A

 

FLOOR PLAN OF SECOND
ADDITIONAL PREMISES

 

 

    	 

    	 

    

 

EXHIBIT B

 

WORK AGREEMENT

 

This Work Agreement
(the “Work Agreement”) is attached to and made a part of that certain Fifth Amendment to Office Lease dated _________
2014, by and between AREP MERIDIAN I LLC, as landlord (“Landlord”), and CHIMERIX, INC., as tenant (“Tenant”),
for the premises (the “Second Additional Premises”) described therein in the building located at 2505 Meridian Parkway,
Durham, North Carolina (the “Building”).

 

A.TENANT IMPROVEMENTS.
Landlord shall furnish and install in the Second Additional Premises in accordance with the terms of this Work Agreement, the improvements
set forth in the Tenant’s Plans (hereinafter defined) which have been approved by Landlord and Tenant in accordance with
Paragraph B, below (the “Tenant Improvements”).

 

B.PLANS AND
SPECIFICATIONS

 

1.Space Plan.
Landlord has retained an architect (the “Space Planner”) who has prepared a space plan (the “Space Plan”)
showing, inter alia, the layout of the Second Additional Premises upon completion of the Tenant Improvements, and certain materials,
finishes and architectural details to be included in the Tenant Improvements, which Space Plan is attached hereto as Schedule
B-1.

 

2.Space Planner.
Landlord shall cause the Space Planner to design the Tenant Improvements and prepare the Contract Documents (hereinafter defined).
The cost of preparation of the Contract Documents shall be borne by Landlord, except as otherwise set forth below.

 

3.Engineers.
Landlord may retain the services of an engineering firm selected by Landlord in its sole discretion (the “Engineers”)
to: (i) design the type, number and location of all mechanical systems in the Second Additional Premises, including without limitation
the heating, ventilating and air conditioning system therein, and to prepare all of the mechanical plans; (ii) assist with the
electrical design of the Second Additional Premises, including the location and capacity of light fixtures, electrical receptacles
and other electrical elements, and to prepare all of the electrical plans; (iii) assist with plumbing related issues involved in
designing the Second Additional Premises and to prepare all of the plumbing plans; and (iv) assist with the structural elements
of the Space Planner’s design of the Second Additional Premises and to prepare all the structural plans. The cost of the
Engineer shall be borne by Landlord, except as otherwise set forth in this Work Agreement.

 

4.Time Schedule.

 

a.Landlord
shall furnish to Tenant for its review and reasonable approval, architectural plans, working drawings and specifications (the “Contract
Documents”) for the construction of the Tenant Improvements in accordance with the Space Plan. Tenant shall advise Landlord
of Tenant’s reasonable approval or disapproval of the Contract Documents, or any of them, within three (3) business days
after Landlord submits the Contract Documents to Tenant; provided, however, that Tenant’s sole basis for rejecting the Contract
Documents shall be if the Contract Documents deviate materially from the Space Plan or if they violate applicable Legal Requirements
(hereinafter defined). Landlord shall revise the Contract Documents to meet Tenant’s reasonable objections, if any, and resubmit
the Contract Documents to Tenant for its review and reasonable approval after Tenant notifies Landlord of Tenant’s reasonable
objections, if any. Tenant shall review and reasonably approve or reject the revised Contract Documents within two (2) business
days after the Landlord resubmits same. Tenant acknowledges and agrees that Landlord shall construct the Tenant Work with Building
standard materials which are readily available in the Raleigh / Durham, North Carolina area, and Landlord shall be entitled to
substitute any element of the Tenant Improvements which may be temporarily unavailable with substantially similar items selected
by Landlord which are available in the Raleigh / Durham, North Carolina area at the time Landlord undertakes the Tenant Improvements.
Such similar items selected by Landlord shall be subject to Tenant’s approval, which approval shall not be unreasonably withheld,
conditioned or delayed. Tenant’s failure to respond within two (2) business days to any request by Landlord that Tenant approve
such items shall be deemed a Tenant Delay hereunder.

 

    	 

    	 

    

 

b.The Space
Plan and the Contract Documents are referred to collectively herein as the “Tenant’s Plans”.

 

5.Change Orders.
Once the Contract Documents have been approved by Landlord and Tenant, no Tenant-requested changes shall be made to the Contract
Documents (“Change Orders”) without the prior written approval of Landlord, which approval shall not be unreasonably
withheld, conditioned or delayed to the extent that Landlord determines that such change does not include any work that will or
may (i) delay the substantial completion of the Tenant Improvements, (ii) affect the base Building structure, (iii) adversely affect
any base Building system or (iv) be or become visible from outside the Premises, in which event Landlord shall have the right to
grant or deny Landlord’s consent to such change in Landlord’s sole and absolute discretion. All requests for Change
Orders shall be in writing. Landlord shall not be responsible for any delay in occupancy by Tenant of the Second Additional Premises,
nor shall the Second Additional Premises Commencement Date be delayed, because of any changes to the Tenant’s Plans requested
by Tenant after approval by Landlord and Tenant. Tenant shall be required to pay the costs incurred in connection with any changes
to the Tenant’s Plans to Landlord, in full, within ten (10) days after invoice. Any costs payable by Tenant to Landlord under
this Work Agreement shall be deemed to be Additional Rent under the Lease, and in the event of any default by Tenant in any payment
thereof, Landlord shall (in addition to all other rights and remedies) have the same rights and remedies arising under the Lease
in the event of a default regarding the payment of Rent.

 

6.Deadlines.
Landlord and Tenant each acknowledge that it is vital that it meet all of the schedule deadlines set forth herein in order to allow
Landlord sufficient time to prepare the Tenant’s Plans, estimate costs, and to substantially complete the work within the
contemplated time frame.

 

C.COST OF TENANT
IMPROVEMENTS. Landlord shall pay for all Construction Costs (hereinafter defined) which it incurs in connection with the construction
of the Tenant Improvements set forth in the initial Tenant’s Plans approved by Landlord and Tenant, except as otherwise provided
in this Work Agreement. As used herein, the term “Construction Costs” means the cost of design and construction of
the Tenant Improvements set forth in the initial Tenant’s Plans approved by Landlord and Tenant, all governmental permits
required for the construction of the Tenant Improvements set forth in the initial Tenant’s Plans approved by Landlord and
Tenant and all construction costs incurred by Landlord in undertaking the Tenant Improvements set forth in the initial Tenant’s
Plans approved by Landlord and Tenant.

 

D.CONSTRUCTION

 

1.Selection of
General Contractor. Once Tenant has approved the Contract Documents, Landlord shall select the contractor (“Contractor”)
which will undertake construction of the Tenant Improvements.

 

2.Tenant Inspection.
Tenant is authorized by Landlord, upon reasonable prior notice to Landlord, to make periodic inspections of the Second Additional
Premises during construction during reasonable business hours, provided Tenant is accompanied by a representative of Landlord or
the Contractor.

 

    	Exhibit B, Page 2

    	 

    

 

3.Delays.

 

a.If Landlord
shall be delayed in substantially completing the Tenant Improvements as a result of any act, neglect, failure or omission of Tenant,
its employees or agents (including without limitation any contractor or subcontractor employed by Tenant performing work at the
Second Additional Premises), including any of the following, such delay shall be deemed a “Tenant Delay”: (1) Tenant’s
failure to timely approve the Contract Documents; (2) Tenant’s failure to timely approve revised Contract Documents after
resubmission by Landlord; (3) Tenant’s delay in submitting or approving any other drawings, plans or specifications; (4)
Tenant’s failure, within two (2) business days after request therefor, to provide Landlord with any other information requested
by Landlord for the purpose of completing the Tenant’s Plans or the ordering of materials or the letting of bids for the
Tenant Improvements; (5) any change by Tenant in the Tenant’s Plans or in any other plan, specification or finish information
furnished by Tenant, after Landlord has commenced the same; (6) delay in the completion of work by any person (other than Landlord
or its contractors) performing work for Tenant; (7) work by Tenant, if any, not being completed on schedule which under good construction
scheduling practices should be completed before some portion of the Tenant Improvements is undertaken or which otherwise interferes
with Landlord undertaking the Tenant Improvements; (8) installation of Tenant’s telephone and/or other communications systems;
(9) any Change Orders; (10) installation by Tenant of any systems furniture in the Second Additional Premises; (11) any act or
omission by Tenant which delays the receipt by Landlord of a certificate of occupancy (or its equivalent) for the Second Additional
Premises; and (12) direction by Tenant that Landlord hold up proceeding or continuing with a segment of the Tenant Improvements
preliminary to a possible Change Order or for any other reason. Landlord shall notify Tenant promptly upon Landlord having actual
notice of any Tenant Delay or events which are reasonably likely to lead to a Tenant Delay. Tenant shall pay to Landlord all additional
costs actually incurred by Landlord resulting from any Tenant Delay, including without limitation actual delay damages awarded
to the Contractor. Any such sums shall be paid to Landlord within ten (10) days after demand therefor by Landlord. As used herein,
the term “Legal Requirements” shall mean any laws, ordinances, regulations and orders of the United States of America,
the State of North Carolina and any other governmental authority with jurisdiction over the Building or the construction of the
Tenant Improvements.

 

b.In the
event that any particular item or items of Tenant Improvements is not readily available in reasonable quantities in, or for delivery
to, the Raleigh / Durham, North Carolina area or requires a long-term lead time to procure, obtain or install (“Long Lead
Items”), the Contractor shall notify Tenant or Landlord (who will notify Tenant) of this fact promptly after ascertaining
same.

 

E.ACCEPTANCE
OF SECOND ADDITIONAL PREMISES. Approximately one (1) day prior to the delivery of possession of the Second Additional Premises
to Tenant with the Tenant Improvements substantially complete, Landlord, Tenant and the Contractor shall make an inspection of
the Second Additional Premises to determine that the construction and installation of the Tenant Improvements has been completed
in accordance with the Tenant’s Plans and this Work Agreement, and to prepare a “Punch List” of work requiring
correction or completion by Landlord. Subject to force majeure, Landlord shall correct or complete all Punch List items within
forty-five (45) days after the Second Additional Premises Commencement Date. Provided Tenant identifies specific Latent Defects
(hereinafter defined) and provides written notice thereof to Landlord within one (1) year after the Second Additional Premises
Commencement Date, Landlord (or Landlord’s contractor, at Landlord’s discretion) shall remedy such Latent Defects promptly
thereafter. As used herein, the term “Latent Defects” shall mean defects in materials and workmanship comprising the
Tenant Improvements that would not be apparent on a reasonable, noninvasive inspection of the Second Additional Premises by a qualified
architect or engineer.

 

    	Exhibit B, Page 3

    	 

    

 

F.CONTRACTOR’S
RULES AND REGULATIONS. Tenant’s contractors, subcontractors and vendors may not enter the Building to perform any work
or installations without Landlord’s prior written consent, which consent shall not be unreasonably withheld, conditioned
or delayed. If Landlord consents to such entry, each contractor, subcontractor or vendor shall observe the construction rules and
regulations promulgated by Landlord from time to time.

 

G.TENANT’S
AGENT. Tenant hereby designates Barbara Berg, whose address is 2505 Meridian Parkway, Suite 340, Durham, North Carolina 27713
and whose telephone number is (919) 313-2969, to act as Tenant’s agent for purposes of authorizing and executing any and
all documents, workletters or other writings and changes thereto needed to effect this Work Agreement, and any and all changes,
additions or deletions to the work contemplated herein, and Landlord shall have the right to rely on any documents executed by
such authorized party.

 

    	Exhibit B, Page 4

    	 

    

 

SCHEDULE B-1

 

SPACE PLAN

 

 

    	 

    	 

    

 

EXHIBIT C

 

DECLARATION OF SECOND
ADDITIONAL PREMISES COMMENCEMENT DATE

 

This Declaration of
Second Additional Premises Commencement Date is made as of ______________, 201__ by and between AREP MERIDIAN I LLC, a Delaware
limited liability company (“Landlord”), and CHIMERIX, INC., a Delaware corporation (“Tenant”), who
agree as follows:

 

1.Landlord and
Tenant entered into that certain Fifth Amendment to Office Lease Agreement dated ____________, 2014 (the “Fifth Amendment”),
in which Landlord leased to Tenant, and Tenant leased from Landlord, certain Second Additional Premises described therein in the
office building located at 2505 Meridian Parkway, Durham, North Carolina (the “Building”). All capitalized terms herein
are as defined in the Fifth Amendment.

 

2.Pursuant to the
Fifth Amendment, Landlord and Tenant agreed to and do hereby confirm that the Second Additional Premises Commencement Date is ______________,
201__.

 

3.Tenant confirms
that:

 

		a.	it has accepted possession of the Second Additional Premises as provided in the Fifth Amendment;

 

		b.	Landlord is not required to perform any work or furnish any improvements to the Second Additional
Premises under the Lease;

 

		c.	Landlord has fulfilled all of its obligations under the Lease as of the date hereof;

 

		d.	the Lease is in full force and effect and has not been modified, altered, or amended, except as
follows: __________________________________; and

 

		e.	there are no set-offs or credits against Rent, and no Security Deposit or prepaid Rent has been
paid except as provided by the Lease.

 

4.The provisions
of this Declaration of Second Additional Premises Commencement Date shall inure to the benefit of, or bind, as the case may require,
the parties and their respective successors and assigns, and to all mortgagees of the Building, subject to the restrictions on
assignment and subleasing contained in the Lease, and are hereby attached to and made a part of the Lease.

 

[signatures appear on
the following page]

 

    	 

    	 

    

 

	 	LANDLORD:
	 	 	 
	 	AREP MERIDIAN I LLC,
	 	a Delaware limited liability company
	 	 	 
	 	 	 
	 	By:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	TENANT:
	 	 	 
	 	CHIMERIX, INC.,
	 	a Delaware corporation
	 	 	 
	 	 	 
	 	By:	 
	 	 	 
	 	 	 

 

    	Exhibit C, Page 2

    	 

    

 

EXHIBIT D

 

FORM OF MEMORANDUM
OF LEASE

 

PREPARED BY AND

AFTER RECORDING MAIL TO:

 

_____________

_____________

_____________

_____________

 

 

 

Memorandum of Lease

 

This Memorandum of
Lease (this “Memorandum”) dated as of ____________, 201__, is made by and between AREP Meridian I LLC, a Delaware limited
liability company (“Landlord”), and Chimerix, Inc., a Delaware corporation (“Tenant”).

 

RECITALS:

 

A.By that certain
Office Lease dated September 1, 2007, as amended (collectively, the “Lease”), by and between Landlord and Tenant, Landlord
leases to Tenant, and Tenant leases from Landlord, the premises containing approximately 17,892 rentable square feet, as more particularly
described in the Lease (the “Premises”), in the building owned by Landlord and having a street address of 2505 Meridian
Parkway, Durham, North Carolina (the “Building”). The Building is located upon the land described on Exhibit A
attached hereto and incorporated herein by this reference (the “Land”).

 

B.Landlord and
Tenant desire to execute and record this Memorandum for the purpose of giving notice of the existence of the Lease.

 

C.Unless otherwise
provided herein, all capitalized words and terms in this Memorandum shall have the same meanings ascribed to such words and terms
as in the Lease.

 

NOW THEREFORE, in consideration
of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:

 

1.Premises.
For and in consideration of the rents reserved and the covenants and agreements contained in the Lease, Landlord has leased unto
Tenant, and Tenant has leased from Landlord, the Premises.

 

2.Lease Term.
The term of the Lease expires on February 28, 2018. Tenant has the right pursuant to the terms of the Lease to extend the term
of the Lease for the three (3) year period commencing on March 1, 2018 and ending on February 28, 2021.

 

3.Intentionally
Omitted.

 

 

    	 

    	 

    

 

4.Subordination.
The Lease is, by its terms, subordinate to each mortgage or deed of trust which may now or hereafter encumber the Land and to all
renewals, modifications, consolidations, replacements and extensions thereof.

 

5.Conflict with
Lease. If there is any conflict between the terms of this Memorandum and the terms of the Lease, the terms of the Lease shall
control.

 

6.Termination
of Memorandum. In consideration of the rights granted to Tenant under the Lease, Tenant has agreed that this Memorandum shall
terminate ipso facto on the earlier of the termination of the Lease or the expiration of the term of the Lease. This clause
shall be self operative and no further instruments are required to effectuate such termination, provided, however, that Tenant
agrees to execute and file a termination of this Memorandum upon Landlord’s request.

 

[Signature Pages Follow]

 

    	Exhibit D, Page 2

    	 

    

 

 

IN WITNESS WHEREOF,
Landlord and Tenant have executed this Memorandum as of the day and year first written above.

 

	 	LANDLORD:
	 	 	 
	 	AREP MERIDIAN I LLC,
	 	a Delaware limited liability company
	 	 	 
	 	 	 
	 	By: 	 
	 	 	Name:  
	 	 	Title:  

 

	STATE OF	 	)	 
	 	 	) SS.	 
	COUNTY OF 	 	)	 

 

I, ___________________
a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that ___________, personally known to me
to be the ___________ of AREP Meridian I LLC, a Delaware limited liability company, and personally known to me to be the same person
whose name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that as such ___________
of AREP Meridian I LLC, a Delaware limited liability company, he/she signed and delivered the said instrument as his/her free and
voluntary act, and as the free and voluntary act and deed of said limited liability company, for the uses and purposes and therein
set forth.

 

Given under my hand and
official seal this ____ day of ___________, 201__.

 

__________________________________________ 

Notary Signature

 

My Commission Expires:
____________________

 

Notary Seal: 

 

    	Exhibit D, Page 3

    	 

    

 

	 	TENANT:
	 	 	 
	 	CHIMERIX,
    INC.,
	 	a
    Delaware corporation
	 	 	 
	 	 	 
	 	By: 	 
	 	 	Name:  
	 	 	Title:  

 

	STATE OF	 	)	 
	 	 	) SS.	 
	COUNTY OF 	 	)	 

 

I, ___________________
a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that _______________________, personally
known to me to be the __________________ of CHIMERIX, Inc., a Delaware corporation, and personally known to me to be the same person
whose name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that as such _________________
of CHIMERIX, Inc., he/she signed and delivered the said instrument and caused the corporate seal of said corporation to be affixed
thereto, pursuant to authority, given by the Board of __________ of said corporation as his/her free and voluntary act, and as
the free and voluntary act and deed of said corporation, for the uses and purposes and therein set forth.

 

Given under my hand and
official seal this ____ day of ___________, 201__.

 

__________________________________________ 

Notary Signature

 

My Commission Expires:
____________________

 

Notary Seal:

  

    	Exhibit D, Page 4

    	 

    

 

EXHIBIT A

 

LEGAL DESCRIPTION OF
THE LAND

 

    	Exhibit D, Page 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]